{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T18:57:02Z","timestamp":1793127422272,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"crossref","award":["CX20210354"],"award-info":[{"award-number":["CX20210354"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81974423"],"award-info":[{"award-number":["81974423"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-83369-5","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T03:11:31Z","timestamp":1735873891000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["FN1 shapes the behavior of papillary thyroid carcinoma through alternative splicing of EDB region"],"prefix":"10.1038","volume":"15","author":[{"given":"Mian","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Long","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Xin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying-Ke","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Jin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"issue":"1","key":"83369_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. Ca-a Cancer J. Clin. 72 (1), 7\u201333 (2022).","journal-title":"Ca-a Cancer J. Clin."},{"issue":"4","key":"83369_CR2","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S2213-8587(21)00027-9","volume":"9","author":"A Miranda","year":"2021","unstructured":"Miranda, A. et al. Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol. 9 (4), 225\u2013234 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"3","key":"83369_CR3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41574-020-00448-z","volume":"17","author":"M Schlumberger","year":"2021","unstructured":"Schlumberger, M. & Leboulleux, S. Current practice in patients with differentiated thyroid cancer. Nat. Reviews Endocrinol. 17 (3), 176\u2013188 (2021).","journal-title":"Nat. Reviews Endocrinol."},{"issue":"4","key":"83369_CR4","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1097\/SLA.0b013e318230036d","volume":"254","author":"X Yu","year":"2011","unstructured":"Yu, X., Wan, Y., Sippel, R. & Chen, H. J. A. o. s., Should all papillary thyroid microcarcinomas be aggressively treated? An analysis of 18,445 cases. Ann. Surg. 254 (4), 653\u2013660 (2011).","journal-title":"Ann. Surg."},{"issue":"10","key":"83369_CR5","doi-asserted-by":"publisher","first-page":"1728","DOI":"10.1093\/annonc\/mdp050","volume":"20","author":"R Sciuto","year":"2009","unstructured":"Sciuto, R. et al. Natural history and clinical outcome of differentiated thyroid carcinoma: a retrospective analysis of 1503 patients treated at a single institution. Ann. Oncol. 20 (10), 1728\u20131735 (2009).","journal-title":"Ann. Oncol."},{"issue":"9","key":"83369_CR6","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1245\/s10434-018-6528-0","volume":"25","author":"DT Hughes","year":"2018","unstructured":"Hughes, D. T. et al. Prophylactic Central Compartment Neck Dissection in Papillary Thyroid Cancer and Effect on Locoregional Recurrence. Ann. Surg. Oncol. 25 (9), 2526\u20132534 (2018).","journal-title":"Ann. Surg. Oncol."},{"issue":"3","key":"83369_CR7","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/01.SLA.0000055273.58908.19","volume":"237","author":"N Wada","year":"2003","unstructured":"Wada, N. et al. Lymph node metastasis from 259 papillary thyroid microcarcinomas - Frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. Ann. Surg. 237 (3), 399\u2013407 (2003).","journal-title":"Ann. Surg."},{"key":"83369_CR8","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1111\/j.1749-6632.1991.tb43701.x","volume":"614","author":"DF Mosher","year":"1991","unstructured":"Mosher, D. F., Fogerty, F. J., Chernousov, M. A. & Barry, E. L. Assembly of fibronectin into extracellular matrix. Ann. N. Y. Acad. Sci. 614, 167\u2013180 (1991).","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"83369_CR9","doi-asserted-by":"publisher","first-page":"4717","DOI":"10.1002\/jcb.26651","volume":"119","author":"X Cai","year":"2018","unstructured":"Cai, X. et al. Down-regulation of FN1 inhibits colorectal carcinogenesis by suppressing proliferation, migration, and invasion. J. Cell. Biochem. 119 (6), 4717\u20134728 (2018).","journal-title":"J. Cell. Biochem."},{"issue":"19","key":"83369_CR10","doi-asserted-by":"publisher","first-page":"8104","DOI":"10.1158\/0008-5472.CAN-08-2132","volume":"68","author":"W Liu","year":"2008","unstructured":"Liu, W., Cheng, S., Asa, S. L. & Ezzat, S. The melanoma-associated antigen A3 mediates fibronectin-controlled cancer progression and metastasis. Cancer Res. 68 (19), 8104\u20138112 (2008).","journal-title":"Cancer Res."},{"issue":"1","key":"83369_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/path.2388","volume":"216","author":"ES White","year":"2008","unstructured":"White, E. S., Baralle, F. E. & Muro, A. F. New insights into form and function of fibronectin splice variants. J. Pathol. 216 (1), 1\u201314 (2008).","journal-title":"J. Pathol."},{"key":"83369_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.addr.2015.11.014","volume":"97","author":"H Kumra","year":"2016","unstructured":"Kumra, H. & Reinhardt, D. P. Fibronectin-targeted drug delivery in cancer. Adv. Drug Deliv Rev. 97, 101\u2013110 (2016).","journal-title":"Adv. Drug Deliv Rev."},{"issue":"3","key":"83369_CR13","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nrc3431","volume":"13","author":"M Xing","year":"2013","unstructured":"Xing, M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat. Rev. Cancer. 13 (3), 184\u2013199 (2013).","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"83369_CR14","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"Cancer Genome Atlas Research","year":"2014","unstructured":"Cancer Genome Atlas Research. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159 (3), 676\u2013690 (2014).","journal-title":"Cell"},{"issue":"4","key":"83369_CR15","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.tcb.2020.12.011","volume":"31","author":"AM Boutelle","year":"2021","unstructured":"Boutelle, A. M. & Attardi, L. D. p53 and Tumor Suppression: It Takes a Network. Trends Cell. Biol. 31 (4), 298\u2013310 (2021).","journal-title":"Trends Cell. Biol."},{"issue":"8","key":"83369_CR16","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41568-020-0262-1","volume":"p53","author":"AJ Levine","year":"2020","unstructured":"Levine, A. J. 800 million years of evolution and 40 years of discovery. Nat. Rev. Cancer. p53 (8), 471\u2013480 (2020). 20.","journal-title":"Nat. Rev. Cancer"},{"issue":"7471","key":"83369_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature12634","volume":"502","author":"C Kandoth","year":"2013","unstructured":"Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502 (7471), 333\u2013339 (2013).","journal-title":"Nature"},{"issue":"4","key":"83369_CR18","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/0092-8674(93)90500-P","volume":"75","author":"WS el-Deiry","year":"1993","unstructured":"el-Deiry, W. S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75 (4), 817\u2013825 (1993).","journal-title":"Cell"},{"issue":"18","key":"83369_CR19","doi-asserted-by":"publisher","first-page":"5189","DOI":"10.1158\/0008-5472.CAN-16-2055","volume":"76","author":"WS El-Deiry","year":"2016","unstructured":"El-Deiry, W. S. p21(WAF1) Mediates Cell-Cycle Inhibition, Relevant to Cancer Suppression and Therapy. Cancer Res. 76 (18), 5189\u20135191 (2016).","journal-title":"Cancer Res."},{"issue":"5","key":"83369_CR20","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s41418-022-00988-z","volume":"29","author":"K Engeland","year":"2022","unstructured":"Engeland, K. Cell cycle regulation: p53-p21-RB signaling. Cell Death Differ. 29 (5), 946\u2013960 (2022).","journal-title":"Cell Death Differ."},{"issue":"22","key":"83369_CR21","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1038\/sj.onc.1201454","volume":"15","author":"S Varmeh-Ziaie","year":"1997","unstructured":"Varmeh-Ziaie, S. et al. Wig-1, a new p53-induced gene encoding a zinc finger protein. Oncogene 15 (22), 2699\u20132704 (1997).","journal-title":"Oncogene"},{"issue":"9","key":"83369_CR22","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/cdd.2011.20","volume":"18","author":"A Vilborg","year":"2011","unstructured":"Vilborg, A., Bersani, C., Wilhelm, M. T. & Wiman, K. G. The p53 target Wig-1: a regulator of mRNA stability and stem cell fate? Cell Death Differ. 18 (9), 1434\u20131440 (2011).","journal-title":"Cell Death Differ."},{"issue":"2","key":"83369_CR23","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.18632\/oncotarget.6557","volume":"7","author":"C Bersani","year":"2016","unstructured":"Bersani, C. et al. Genome-wide identification of Wig-1 mRNA targets by RIP-Seq analysis. Oncotarget 7 (2), 1895\u20131911 (2016).","journal-title":"Oncotarget"},{"issue":"3","key":"83369_CR24","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.molcel.2020.10.022","volume":"80","author":"KT Bieging-Rolett","year":"2020","unstructured":"Bieging-Rolett, K. T. et al. Zmat3 Is a Key Splicing Regulator in the p53 Tumor Suppression Program. Mol. Cell. 80 (3), 452\u2013469 (2020). e9.","journal-title":"Mol. Cell."},{"issue":"2","key":"83369_CR25","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0304-3835(97)00353-4","volume":"121","author":"S Ryu","year":"1997","unstructured":"Ryu, S., Jimi, S. & Takebayashi, S. Thyroid carcinoma distinctively expresses intracellular fibronectin in vivo. Cancer Lett. 121 (2), 189\u2013193 (1997).","journal-title":"Cancer Lett."},{"key":"83369_CR26","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.canlet.2018.10.018","volume":"440","author":"HF Sun","year":"2019","unstructured":"Sun, H. F. et al. Loss of TMEM126A promotes extracellular matrix remodeling, epithelial-to-mesenchymal transition, and breast cancer metastasis by regulating mitochondrial retrograde signaling. Cancer Lett. 440, 189\u2013201 (2019).","journal-title":"Cancer Lett."},{"issue":"1","key":"83369_CR27","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/0092-8674(92)90115-S","volume":"69","author":"RO Hynes","year":"1992","unstructured":"Hynes, R. O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69 (1), 11\u201325 (1992).","journal-title":"Cell"},{"issue":"4","key":"83369_CR28","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/0092-8674(88)90580-6","volume":"53","author":"M Obara","year":"1988","unstructured":"Obara, M., Kang, M. S. & Yamada, K. M. Site-directed mutagenesis of the cell-binding domain of human fibronectin: separable, synergistic sites mediate adhesive function. Cell 53 (4), 649\u2013657 (1988).","journal-title":"Cell"},{"issue":"1\u20133","key":"83369_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0014-5793(02)03004-1","volume":"524","author":"MT Wilhelm","year":"2002","unstructured":"Wilhelm, M. T., M\u00e9ndez-Vidal, C. & Wiman, K. G. Identification of functional p53-binding motifs in the mouse wig-1 promoter. FEBS Lett. 524 (1\u20133), 69\u201372 (2002).","journal-title":"FEBS Lett."},{"issue":"4","key":"83369_CR30","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.cmet.2023.01.011","volume":"35","author":"K Kuramoto","year":"2023","unstructured":"Kuramoto, K., Liang, H. J., Hong, J. H. & He, C. C. Exercise-activated hepatic autophagy via the FN1-05?1 integrin pathway drives metabolic benefits of exercise. Cell Metabol. 35 (4), 620\u2013 (2023).","journal-title":"Cell Metabol."},{"key":"83369_CR31","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.matbio.2019.07.006","volume":"85\u201386","author":"AJ Berger","year":"2020","unstructured":"Berger, A. J. et al. Scaffold stiffness influences breast cancer cell invasion via EGFR-linked Mena upregulation and matrix remodeling. Matrix Biol. 85\u201386, 80\u201393 (2020).","journal-title":"Matrix Biol."},{"issue":"1","key":"83369_CR32","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.immuni.2017.12.007","volume":"48","author":"A Glasner","year":"2018","unstructured":"Glasner, A. et al. NKp46 Receptor-Mediated Interferon-\u03b3 Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis. Immunity 48 (1), 107\u2013 (2018).","journal-title":"Immunity"},{"issue":"19","key":"83369_CR33","first-page":"5603","volume":"62","author":"T Fukuda","year":"2002","unstructured":"Fukuda, T. et al. Mice lacking the EDB segment of fibronectin develop normally but exhibit reduced cell growth and fibronectin matrix assembly\u2009<\u2009i\u2009>\u2009in vitro. Cancer Res. 62 (19), 5603\u20135610 (2002).","journal-title":"Cancer Res."},{"key":"83369_CR34","doi-asserted-by":"publisher","first-page":"S86","DOI":"10.1007\/s00259-010-1503-4","volume":"37","author":"R Haubner","year":"2010","unstructured":"Haubner, R., Beer, A. J., Wang, H. & Chen, X. Y. Positron emission tomography tracers for imaging angiogenesis. Eur. J. Nucl. Med. Mol. Imaging. 37, S86\u2013S103 (2010).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"83369_CR35","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1517\/14728222.9.3.491","volume":"9","author":"A Menrad","year":"2005","unstructured":"Menrad, A. & Menssen, H. D. ED-B fibronectin as a target for antibody-based cancer treatments. Expert Opin. Ther. Targets. 9 (3), 491\u2013500 (2005).","journal-title":"Expert Opin. Ther. Targets"},{"issue":"3","key":"83369_CR36","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1158\/2326-6066.CIR-20-0280","volume":"9","author":"J Wagner","year":"2021","unstructured":"Wagner, J. et al. Antitumor Effects of CAR T Cells Redirected to the EDB Splice Variant of Fibronectin. Cancer Immunol. Res. 9 (3), 279\u2013290 (2021).","journal-title":"Cancer Immunol. Res."},{"key":"83369_CR37","doi-asserted-by":"crossref","unstructured":"Lu, Z. R., Laney, V. & Li, Y. J. Targeted Contrast Agents for Magnetic Resonance Molecular Imaging of Cancer (Accounts of Chemical Research, 2022).","DOI":"10.1021\/acs.accounts.2c00346"},{"issue":"5","key":"83369_CR38","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1101\/gad.1398206","volume":"20","author":"NP Gomes","year":"2006","unstructured":"Gomes, N. P. et al. Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program. Genes Dev. 20 (5), 601\u2013612 (2006).","journal-title":"Genes Dev."},{"issue":"7","key":"83369_CR39","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41591-018-0043-5","volume":"24","author":"A Janic","year":"2018","unstructured":"Janic, A. et al. DNA repair processes are critical mediators of p53-dependent tumor suppression. Nat. Med. 24 (7), 947\u2013 (2018).","journal-title":"Nat. Med."},{"issue":"35","key":"83369_CR40","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1038\/onc.2013.594","volume":"33","author":"C Bersani","year":"2014","unstructured":"Bersani, C., Xu, L. D., Vilborg, A., Lui, W. O. & Wiman, K. G. Wig-1 regulates cell cycle arrest and cell death through the p53 targets FAS and 14-3-3\u03c3. Oncogene 33 (35), 4407\u20134417 (2014).","journal-title":"Oncogene"},{"key":"83369_CR41","doi-asserted-by":"crossref","unstructured":"Lim, L. & Sharp, P. J. M. biology, c., Alternative splicing of the fibronectin EIIIB exon depends on specific TGCATG repeats. 18 (7), 3900\u20133906. (1998).","DOI":"10.1128\/MCB.18.7.3900"},{"key":"83369_CR42","doi-asserted-by":"crossref","unstructured":"Liu, M. et al. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT\/mTOR pathway. Biosci. Rep. 42 (1). (2022).","DOI":"10.1042\/BSR20210245"},{"key":"83369_CR43","first-page":"0","volume":"51","author":"K Minoru","year":"2022","unstructured":"Minoru, K., Miho, F., Yoko, S., Masayuki, K. & Mari, I. W. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, 0 (2022).","journal-title":"Nucleic Acids Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83369-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83369-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83369-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,4]],"date-time":"2025-01-04T02:03:25Z","timestamp":1735956205000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-83369-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["83369"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-83369-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"30 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was provided by the Committees for Ethical Review of Research involving Human Subjects and Animal experiments at Xiangya Hospital, Central South University (No. 2019030140).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"327"}}